The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline

• Published in: Medicine (Baltimore) 2022-10, Vol.101 (41), p.e30739-e30739
• Main Authors: Zhang, Miao, Sun, Ming-Yue, Chen, Qi-Ting, Xu, Feng-Qin, Chen, Zong-Zheng, Wei, Wen-Bo, Wang, Rui-Ting, Xu, Gui-Peng, Yin, Hui-Jun
• Format: Article
• Language: English
• Subjects: Systematic Review and Meta-Analysis
• ISSN: 1536-5964; 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000030739

BACKGROUNDPercutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available. METHODSSeven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool. RESULTSOne thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group. CONCLUSIONYQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD.